| Up
2005D-0202:
Guidance for Industry on Bar Code Label Requirements; Questions
and Answers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| GDL1
|
| 06/07/2005
|
| 06/07/2005
|
| Federal
Government
|
| Guidance
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
| Signature:
|
| Guidance
|
|
|
|
|
|
|
|
| NAD1
|
|
|
| 06/06/2005
|
| FDA
|
| FDA
|
| 06/07/2005
|
| 33182-33183
|
| 08/08/2005
|
| pdf
|
|
|
|
|
| Signature:
|
| SHUREN, JEFFREY
|
|
|
|
|
| EC1
|
| 06/17/2005
|
| 06/09/2005
|
| Health Professional
|
| Bayshore Community
Hospital
|
|
|
|
|
|
|
| htm
|
|
|
|
|
| Signature:
|
| Levanda, Matthew
|
|
|
|
|
| EC2
|
| 08/01/2005
|
| 07/29/2005
|
| Private Industry
|
| Pfizer Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Guazzaroni Jacobs, Maria
|
|
|
|
|
| C1
|
| 08/02/2005
|
| 08/01/2005
|
| Drug Industry
|
| Pfizer Inc
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Gerald P Migliaccio
|
|
|
|
|
| C2
|
| 08/08/2005
|
| 08/04/2005
|
| Drug Industry
|
| Bristol-Myers Squibb
(BMS)
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Richard L. Wolgemuth, PhD
|
|
|
|
|
| C3
|
| 08/05/2005
|
| 08/04/2005
|
| Association
|
| Health Industry
Group Purchasing Association (HIGPA)
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
|
| Signature:
|
| Robert Betz, PhD
|
|
|
|
|
| C4
|
| 08/09/2005
|
| 08/08/2005
|
| Drug Industry
|
| Wyeth Pharmaceuticals
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Roy J. Baranello, Jr.
|
|
|
|
|
| EC3
|
| 08/10/2005
|
| 08/08/2005
|
| Health Care
Association
|
| Healthcare
Information and Management Systems Soci
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
|
|
|
| Signature:
|
| Leary, Thomas
| |
|
|
|
| C5
|
| 08/16/2005
|
| 08/15/2005
|
| Drug Industry
|
| Roxane Laboratories,
Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Martin J. Williamson, PhD
| |
|
|
|
| C6
|
| 11/07/2005
|
| 11/02/2005
|
| Drug Industry
|
| GlaxoSmithKline (GSK)
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Janice M. Whitaker
|
|
|
|
|
| FONS2
|
| 04/27/2006
|
| 04/27/2006
|
| Federal Government
|
| Number not used
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GDL2
|
| 04/26/2006
|
| 04/26/2006
|
| Federal Government
|
| Guidance
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
|
|
| NAD2
|
|
|
| 04/26/2006
|
| FDA
|
| FDA
|
| 04/27/2006
|
| 24856-24857
|
| 04/26/2007
|
| htm | pdf
|
|
|
|
|
| Signature:
|
| SHUREN, JEFFREY
|
|
|
|
Top | Up
Page last updated
May 10, 2006
kk
Dockets Home Page | Dockets
Contacts and Location | Operating
Status | Item
Code Definitions | Federal
Register
FDA Home Page | Search
FDA Site | FDA A-Z Index
| Contact FDA
FDA/Dockets Management |
